Sanofi-Aventis returned rights to a mid-stage type 2 diabetes drug to Metabolex Inc.
The Paris company said it opted to terminate its right to MBX-2982, the center of a July 2010 deal that Sanofi and Hayward-based Metabolex. A year ago, the companies said the deal could be worth up to $375 million in milestone payments.
